CLEC12A and Miyoshi myopathy: Previously, such approaches were successfully used to identify tumor-specific antibodies like the anti-human C-type lectin-like molecule-1 antibodies for AML or anti-human ICAM-1 antibodies for MM therapy (8, 23, 47).